Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil速9 in Healthy Females 18-26 Years of Age
This study is designed to compare the immunogenicity of a novel recombinant human papillomavirus vaccine (types 6,11,16,18,31,33,45,52,58 )(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., with Gardasil速9 in females 18-26 Years of Age.
Cervical Cancer|Condylomata Acuminata
BIOLOGICAL: Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|BIOLOGICAL: Gardasil速9
Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific neutralizing antibody level, Anti-HPV 6,11,16,18,31,33,45,52 and 58 seroconversion rates and geometric mean concentrations at months 7, 7 months after the first dose
safety1:Local and systematic adverse events/reactions occurred within 7 days after each vaccination., Local and systematic adverse events/reactions occurred within 7 days after each vaccination., During the 7-day period following each vaccination|safety2:Adverse events/reactions occurred within 30 days after each vaccination., Adverse events/reactions occurred within 30 days after each vaccination., Within 30 days (Day 0-30) after any vaccination|safety3:Severe adverse events occurred throughout the study. To evaluate number of SAEs compared with the control vaccine., Severe adverse events occurred throughout the study. To evaluate number of SAEs compared with the control vaccine., Up to 8 month|safety4:Pregnancy and pregnancy outcome. To evaluate number of births and terminations compared with the control vaccine., Pregnancy and pregnancy outcome. To evaluate number of births and terminations compared with the control vaccine., Up to 8 month
Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific IgG antibody level, Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations at months 7(type specific IgG antibody), 7 months after the first dose
This study is designed to compare the immunogenicity of a novel recombinant human papillomavirus vaccine (types 6,11,16,18,31,33,45,52,58 )(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., with Gardasil速9 in females 18-26 Years of Age.